Palmisciano Paolo, Ferini Gianluca, Watanabe Gina, Ogasawara Christian, Lesha Emal, Bin-Alamer Othman, Umana Giuseppe E, Yu Kenny, Cohen-Gadol Aaron A, El Ahmadieh Tarek Y, Haider Ali S
Department of Neurosurgery, University of Cincinnati College of Medicine, Cincinnati, OH 45229, USA.
Department of Radiation Oncology, REM Radioterapia srl, 95029 Viagrande, Italy.
Cancers (Basel). 2022 May 19;14(10):2507. doi: 10.3390/cancers14102507.
Background: Gliomas infiltrating the corpus callosum (G-I-CC) majorly impact patient quality-of-life, but maximally safe tumor resection is challenging. We systematically reviewed the literature on G-I-CC. Methods: PubMed, EMBASE, Scopus, Web of Science, and Cochrane were searched following the PRISMA guidelines to include studies of patients with G-I-CC. Clinicopathological features, treatments, and outcomes were analyzed. Results: We included 52 studies comprising 683 patients. Most patients experienced headache (33%), cognitive decline (18.7%), and seizures (17.7%). Tumors mostly infiltrated the corpus callosum genu (44.2%) with bilateral extension (85.4%) into frontal (68.3%) or parietal (8.9%) lobes. Most G-I-CC were glioblastomas (84.5%) with IDH-wildtype (84.9%) and unmethylated MGMT promoter (53.5%). Resection (76.7%) was preferred over biopsy (23.3%), mostly gross-total (33.8%) and subtotal (32.5%). The tumor-infiltrated corpus callosum was resected in 57.8% of cases. Radiation was delivered in 65.8% of patients and temozolomide in 68.3%. Median follow-up was 12 months (range, 0.1−116). In total, 142 patients (31.8%) experienced post-surgical complications, including transient supplementary motor area syndrome (5.1%) and persistent motor deficits (4.3%) or abulia (2.5%). Post-treatment symptom improvement was reported in 42.9% of patients. No differences in rates of complications (p = 0.231) and symptom improvement (p = 0.375) were found in cases with resected versus preserved corpus callosum. Recurrences occurred in 40.9% of cases, with median progression-free survival of 9 months (0.1−72). Median overall survival was 10.7 months (range, 0.1−116), significantly longer in low-grade tumors (p = 0.013) and after resection (p < 0.001), especially gross-total (p = 0.041) in patients with high-grade tumors. Conclusions: G-I-CC show clinicopathological patterns comparable to other more frequent gliomas. Maximally safe resection significantly improves survival with low rates of persistent complications.
浸润胼胝体的胶质瘤(G-I-CC)对患者生活质量有重大影响,但最大程度安全切除肿瘤具有挑战性。我们系统回顾了关于G-I-CC的文献。方法:按照PRISMA指南检索PubMed、EMBASE、Scopus、Web of Science和Cochrane数据库,纳入G-I-CC患者的研究。分析临床病理特征、治疗方法和结果。结果:我们纳入了52项研究,共683例患者。大多数患者有头痛(33%)、认知功能下降(18.7%)和癫痫发作(17.7%)。肿瘤大多浸润胼胝体膝部(44.2%),双侧延伸至额叶(68.3%)或顶叶(8.9%)(85.4%)。大多数G-I-CC为胶质母细胞瘤(84.5%),异柠檬酸脱氢酶野生型(84.9%),O6-甲基鸟嘌呤-DNA甲基转移酶启动子未甲基化(53.5%)。与活检(23.3%)相比,切除术(76.7%)更受青睐,大多为全切(33.8%)和次全切(32.5%)。57.8%的病例切除了肿瘤浸润的胼胝体。65.8%的患者接受了放疗,68.3%的患者接受了替莫唑胺治疗。中位随访时间为12个月(范围0.1 - 116个月)。共有142例患者(31.8%)出现术后并发症,包括短暂性辅助运动区综合征(5.1%)、持续性运动功能障碍(4.3%)或意志缺失(2.5%)。42.9%的患者报告治疗后症状改善。在切除胼胝体与保留胼胝体的病例中,并发症发生率(p = 0.231)和症状改善率(p = 0.375)无差异。40.9%的病例出现复发,无进展生存期的中位数为9个月(0.1 - 72个月)。总生存期的中位数为10.7个月(范围0.1 - 116个月),在低级别肿瘤患者(p = 0.013)和切除术后(p < 0.001)明显更长,尤其是高级别肿瘤患者的全切术后(p = 0.041)。结论:G-I-CC的临床病理模式与其他更常见的胶质瘤相似。最大程度安全切除可显著提高生存率,持续性并发症发生率低。